A randomised trial of a Haemophilus influenzae type b conjugate vaccine in a developing country for the prevention of pneumonia - Ethical considerations

International Journal of Tuberculosis and Lung Disease

Volumn 3, Issue 9, 1999, Pages 749-755

  Mulholland, Kim ^a   Smith, P G ^c   Broome, C V ^b   Gaye, A ^c   Whittle, H ^c   Greenwood, B M ^c  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c NONE

Author keywords

Developing countries; Haemophilus influenzae type b; Informed consent; Vaccine trials

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE; PLACEBO;

BACTERIAL MENINGITIS; BACTERIAL PNEUMONIA; CHILDHOOD DISEASE; CLINICAL TRIAL; CONJUGATE; DEVELOPING COUNTRY; DRUG COST; DRUG EFFICACY; GAMBIA; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; INFORMED CONSENT; MEDICAL ETHICS; PRIORITY JOURNAL; REVIEW; VACCINATION; WORLD HEALTH ORGANIZATION;

BIOMEDICAL AND BEHAVIORAL RESEARCH; HEALTH CARE AND PUBLIC HEALTH;

ETHICS, MEDICAL; GAMBIA; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HUMANS; PNEUMONIA, BACTERIAL; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME; VACCINES, CONJUGATE;

EID: 0032882027     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Adams W G, Deaver K A, Cochi S L, et al. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA 1993; 269: 221-226.
2. Ferreccio C, Ortiz E, Astroza L, et al. A population-based retrospective assessment of the disease burden resulting from invasive Haemophilus influenzae in infants and young children in Santiago, Chile. Pediatr Infect Dis J 1990; 9: 488-494.
3. Bijlmer H A, van Alphen L, Greenwood B M, et al. The epidemiology of Haemophilus influenzae meningitis in children under 5 years of age in The Gambia, West Africa. J Infect Dis 1990; 161: 1210-1215.
4. Adegbola R A, Mulholland E K, Falade A G, et al. Haemophilus influenzae type b disease in the Western Region of The Gambia: background surveillance for a vaccine efficacy trial. Ann Trop Paediatr 1996; 16: 103-111.
5. Greenwood B M. Epidemiology of acute lower respiratory tract infections, especially those due to Haemophilus influenzae type b, in The Gambia, West Africa. J Infect Dis 1992; 165(Suppl 1): S26-S28.
6. Wall R A, Corrah P T, Mabey D C W, Greenwood B M. The etiology of lobar pneumonia in The Gambia. Bull World Health Organ 1986; 64: 553-558.
7. Adegbola R A, Falade A G, Samb B, et al. The etiology of pneumonia in malnourished and well-nourished Gambian children. Pediatr Infect Dis J 1994; 13: 975-982.
8. Falade A G, Mulholland E K, Adegbola R A, Greenwood B M. Bacterial isolates from blood and lung aspirate cultures in Gambian children with lobar pneumonia. Ann Trop Paediatr 1997; 17: 315-319.
9. Forgie I M, O'Neill K P, Lloyd-Evans N, et al. Etiology of acute lower respiratory tract infections in Gambian children: I. Acute lower respiratory tract infections in infants presenting at the hospital. Pediatr Infect Dis J 1991; 10: 33-41.
10. Forgie I M, O'Neill K P, Lloyd-Evans N, et al. Etiology of acute lower respiratory tract infections in Gambian children: II. Acute lower respiratory tract infection in children ages one to nine years presenting at the hospital. Pediatr Infect Dis J 1991; 10: 42-47.
11. Campbell H, Byass P, Ahonkhai V I, et al. Serologic responses to an Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine in very young Gambian infants. Pediatrics 1990; 86: 102-107.
12. Mulholland E K, Todd J, Rowe M, et al. Persistence of anti-body at 18 months following vaccination of young Gambian infants with PRP-OMPC conjugate vaccine against Haemophilus influenzae type b. Ann Trop Paediatr 1993, 13: 153-158.
13. Mulholland E K, Ahonkhai V I, Greenwood A M, et al. The safety and immunogenicity of Haemophilus influenzae type b-Neisseria meningitidis Group B outer membrane protein complex conjugate vaccine mixed in the syringe with Diphtheria-Tetanus-Pertussis vaccine in young Gambian infants. Pediatr Infect Dis J 1993; 12: 632-637.
14. Mulholland E K, Byass P, Campbell H, et al. The immunogenicity and safety of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in Gambian infants. Ann Trop Paed 1994; 14: 183-188.
15. Mulholland E K, Hoestermann A, Ethevenaux C, et al. The use of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine mixed with Diphtheria/Tetanus/Pertussis vaccine in Gambian infants. Vaccine 1996; 14: 905-909.
16. Mulholland E K, Hilton S, Adegbola R A, et al. Randomized trial of Haemophilus influenzae type b-tetanus protein conjugate vaccine for prevention of pneumonia and meningitis in Gambian infants. Lancet 1997; 349: 1191-1197.
17. Santosham M, Wolff M, Reid R, et al. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. N Engl J Med 1991; 324: 1767-1772.
18. Black S B, Shinefield H R, Fireman B, Hiatt R, Polen M, Vittinghoff E. Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. Pediatr Infect Dis J 1991; 10: 97-104.
19. Ward J, Brenneman G, Letson G W, Heyward W L. Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. The Alaska H. influenzae Vaccine Study Group. N Engl J Med 1990; 323: 1393-1401.
20. Eskola J, Käyhty H, Takala A K, et al. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. N Engl J Med 1990; 323: 1381-1387.
21. Leach A, Hilton S, Greenwood B M, et al. An evaluation of the process of informed consent applied in the trial of an Haemophilus influenzae type b vaccine in The Gambia. Soc Sci Med 1999; 48: 139-148.
22. Anonymous. The Children's Vaccine Initiative and the Global Programme for Vaccines and Immunization - Recommendations from the Special Advisory Group of Experts. Weekly Epidemiological Record 1997; 72: 237-244.